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Summary of main point:  A high percentage of patients who tested positive for vancomycin 
resistant Enterococcus (VRE) converted to VRE negative after administration of a microbiota-
based drug targeted at recurrent Clostridium difficile infection. 
 
Abstract 
Background: Vancomycin-resistant Enterococcus (VRE) is a major healthcare-associated 
pathogen and a well-known complication among transplant and immunocompromised patients. 
We report on stool VRE clearance in a post hoc analysis of the Phase 2 PUNCH CD study 
assessing a microbiota-based drug for recurrent Clostridium difficile infection.     
 
Methods: A total of 34 patients enrolled in the PUNCH CD study received 1 or 2 doses of 
RBX2660 (microbiota suspension). Patients were requested to voluntarily submit stool samples 
at baseline and at 7, 30 and 60 days and 6-months after the last administration of RBX2660. 
Stool samples were tested for VRE using bile esculin azide agar with 6 µg/ml vancomycin and 
gram staining. Vancomycin resistance was confirmed by Etest.  
 
Results: VRE status (at least 1 test result) was available for 30 patients. All stool samples for 
19 patients (63.3%, mean age 61.7 years, 68% female) tested VRE negative. Eleven patients 
(36.7%, mean age 75.5 years, 64% female) were VRE positive at the first test (baseline or 7-
day follow-up). Of these patients, 72.7%, n=8 converted to negative as of the last available 
follow-up (30 or 60 days or 6-months). Of the other 3: 1 died (follow-up data not available); 1 
patient remained positive at all follow-ups; 1 patient retested positive at 6-months with negative 






















Conclusions: Although based on a small sample size, this secondary analysis demonstrated 
the possibility of successfully converting a high percentage of VRE positive patients to negative 
in a recurrent CDI population with RBX2660.  
 
Introduction 
Vancomycin-resistant Enterococcus (VRE) is a major healthcare-associated pathogen. VRE 
infection is a well-known complication among critically ill, transplant and immunocompromised 
patients [1]. VRE colonization precedes infection, and vancomycin resistance is an independent 
predictor of mortality in patients with enterococcal bacteremia [1]. Colonization and infection are 
also associated with increased hospital length of stay [2,3] and costs [2,3], and carriers are at 
increased risk for infection and a source of transmissions to others. Controlling transmission in a 
healthcare setting can be challenging [4].  Clostridium difficile infection (CDI), likewise, is a 
challenging healthcare-associated infection (HAI) and can result in severe morbidity and 
mortality. CDI is now the most common cause of HAI and the leading cause of gastroenteritis-
associated deaths in the U.S. A recent study found that CDI was responsible for approximately 
453,000 infections and 29,000 deaths in the US in 2011[5]. Recurrence is an especially 
challenging aspect of treating CDI, with up to 25% of patients experiencing disease recurrence, 
usually within 30 days of treatment [6]. 
 
Both VRE and CDI share similar risk factors, including contact with the healthcare system, 
antimicrobial exposures, acuity of underlying illness, and immunocompromised status [7].  
Increased frequencies of VRE colonization and infection have been observed to occur in 





















also found in 58.7% of cases. There was also a greater prevalence of co-infection with multidrug 
resistant organisms (MDRO) in the VRE positive patients [8].   Antimicrobial-induced 
perturbation of the gut microbiota may contribute to both VRE and CDI, allowing acquisition and 
over growth, and then persistence of colonization. Controlling the spread of VRE in the 
healthcare environment is difficult.  Patients can remain colonized with VRE for prolonged 
periods of time, serving as a reservoir for transmission and infection to others. Decolonization of 
VRE is extremely difficult if not impossible. While non-absorbed antimicrobials are effective in 
suppressing VRE, recurrence of colonization is common [9, 10].  While non-absorbed 
antimicrobials are effective in suppressing VRE, recurrence of colonization is com   
Antimicrobial treatment options can have rate limiting toxicities, and resistance to antimicrobials 
with activity against VRE is increasing. VRE infection also significantly increases length of stay 
and hospitalization costs [2,11].  
 
There is growing recognition that commensal bacteria present in the intestinal microbiome play 
an important role in colonization resistance to pathogens, including C. difficile and VRE, and 
that antimicrobial use can disrupt this protection and enable a cycle of persistence/reinfection.  
In the case of CDI, studies suggest that restoration of the gut microbiota is necessary to prevent 
or mitigate recurrence [12].  Fecal microbiota transplantation (FMT) has been used to 
repopulate the intestines with normal microbiota and has been demonstrated as effective in the 
treatment of recurrent CDI with few adverse events [13, 14].  We report on clearance of VRE in 
stool in a secondary analysis of the PUNCH CD study, a Phase 2 open-label study assessing 
























Forty patients with recurrent CDI at 11 centers in the U.S. were enrolled in the PUNCH CD 
study between August 15 and December 16, 2013 [15]. Major inclusion criteria were: age ≥ 18 
years old and at least two recurrences of CDI after a primary episode or at least two episodes of 
severe CDI resulting in hospitalization. Completion of a 10-14 day course of oral antimicrobials 
for CDI, the last 7 days of which were standardized to oral vancomycin (125 mg four times daily) 
was required, followed by a 24-48 hour washout period prior to RBX2660 administration. A 
single dose of RBX2660 was administered via enema. A second dose was permitted if CDI 
recurrence was suspected within 8 weeks of the first dose. No antimicrobials for the treatment of 
CDI or bowel prep were given before the second dose.  Major exclusion criteria were: history of 
inflammatory bowel disease (ulcerative colitis, Crohn’s disease or microscopic colitis); irritable 
bowel syndrome; chronic diarrhea; celiac disease; colostomy; evidence of active, severe colitis; 
planned surgery requiring perioperative antibiotics within 6 months of study enrollment; 
compromised immune system and white blood cell count <1000 cells/µL.  
 
RBX2660 
RBX2660 is a microbiota-based drug sourced from live human-derived microbes. Donors 
underwent a comprehensive initial health and lifestyle questionnaire and then provided blood 
and stool samples that were tested for a wide variety of pathogens. RBX2660 is produced with 
Good Manufacturing Practices (GMP) and a standardized chain of custody. Product is stored in 
a secure location at ≤ -80 ºC prior to shipment. Each 150 mL dose (50 g of stool and 0.9% 
saline/polyethylene glycol 3350 vehicle) contains ≥ 107 microbes/mL and is available in a single 






















VRE Testing Protocol 
Baseline stool testing of the study patients included culture for VRE. Additionally, patients were 
requested to voluntarily submit stool samples at 7, 30 and 60 days and 6-months after the last 
administration of RBX2660. Stool samples were shipped on ice to Fairview Diagnostic 
Laboratories, Minneapolis, MN, USA laboratory via overnight delivery. Lab requirements for 
testing were fresh stool, within 72 hours of collection; refrigerated if not tested directly after 
collection. To determine the presence of VRE, stool was inoculated onto bile esculin azide agar 
with 6 μg/ml vancomycin (Remel, Lenaxa, Kansas, USA). Enterococcal isolates were identified 
based on colony morphology, Gram stain, and biochemical testing. Suspected enterococcal 
isolates were sub-cultured on blood agar with a vancomycin disk and vancomycin resistance 
was confirmed by Etest, 
 
Antimicrobial Use Exposure Post-RBX2660 Administration  
After RBX2660 administration, physicians could treat patients with antimicrobials as medically 
necessary. Medication use was collected on the case report form in free-form text for all patients 
enrolled in the PUNCH CD study. Data on post-RBX2660 antimicrobial administration was 
abstracted and placed on a timeline for the purposes of determining whether or not VRE was 
detectable in fecal specimens throughout the course of the study.  
 
Definitions 
For the PUNCH CD study, successful treatment of CDI was defined as the absence of 
Clostridium difficile associated diarrhea at 56 days after the last dose of RBX2660. For the VRE 
analysis, patients were grouped into always negative and positive at least once.  A baseline, i.e. 





















the pre-RBX2660 and day 7 follow-up stool specimens were used to identify patients likely 
colonized with VRE at time of RBX2660 administration. VRE clearance was defined as no stool 
specimens positive for VRE after at least one positive stool test.   
 
Statistical Methods 
Descriptive statistics were used for data analysis. This secondary analysis was not powered to 





A total of 34 patients received 1 or 2 doses of RBX2660.  Of these, 30 patients had at least 1 
stool sample available for VRE testing.  Of these patients, the mean age was 66.7 years with a 
range of 26.7-89.5 years. Twenty (66.6%) were female and 29 (96.6%) were white (Table 1). 
Patients with at least one stool positive for VRE were older than patients without stool positive 
for VRE (75.5 versus 61.7 years old). Prior to study enrollment, patients had been on a variety 
of CDI treatment regimens, primarily standard dose vancomycin but also vancomycin taper and 
standard dose fidaxomicin; 1 patient had been on a fidaxomicin taper. 
 
VRE Status 
All stool samples submitted for testing were found acceptable by the laboratory performing VRE 
testing. A total of 30/34 (88%) of patients treated with RBX2660 submitted at least 1 stool for 





















positive for VRE at the first test (baseline or 7-day follow-up). Of the patients who were positive 
for VRE at least once, 72.7% (n=8) converted to negative as of the last available follow-up. The 
proportion of patients testing positive for VRE after the last dose of RBX2660 decreased over 
time (Figure 1). Three patients were classified as having failed to clear VRE: One patient died of 
respiratory failure unrelated to RBX2660 administration soon after FMT. Follow-up VRE 
resolution data was, therefore, not available. A second patient remained VRE positive at all 
follow-ups (prescribed a 14-day course of vancomycin at 16 days post-RBX2660 
administration). The third patient retested positive at 6 months after having negative tests in the 
interim. This patient was VRE positive at 9 days post-RBX 2660 administration and then tested 
VRE negative at the 1- month and 2-month follow-ups. Subsequently, this patient developed 
several episodes of recurrent CDI and received 8 courses of antimicrobials between the last 
negative stool test for VRE and the 6 month specimen which was positive. 
 
Antimicrobial use post-RBX2660 administration was analyzed for the 11 patients who were VRE 
positive on their first test. Patients received antimicrobials post-RBX2660 administration 
primarily for CDI or diarrhea but also for pneumonia, urinary tract infection, sinus infection, 
abscess, and non-specified bacterial infection. Of these patients, 6 received antimicrobials post-
RBX2660 administration; the mean duration of their antimicrobial exposure post-RBX2660 
administration was 6.2 (range 1 to 14) days. Considering only the  patients who were initially 
VRE positive and converted to VRE negative at last assessment, 4 received antimicrobials post-
RBX2660 administration; mean duration was 7.0 (range 2 to 13) days.  In the 11 patients who 
tested VRE positive at least once, the antimicrobials prescribed post-RBX2660 administration 
were: vancomycin (n=5); fidaxomicin (n=3); metronidazole (n=1); ciprofloxacin (n=2); amoxicillin 
(n=2); doxycycline (n=1); and other (n=5). Analysis of variance shows that antimicrobial use was 























VRE colonization and CDI share similar risk factors, and VRE infection and colonization have 
been observed to occur in tandem with CDI. Of 158 cases of CDI evaluated by Fujitani, et al. 
[8], 55.7% were colonized with VRE. In this subset of 30 patients with recurrent CDI who were 
enrolled PUNCH CD study, 36.7% had stool positive for VRE at baseline. The major risk factor 
for acquiring and developing infections from both VRE [16-18] and C. difficile is antimicrobial 
exposure [19-21]. There is recognition that antimicrobials disturb the microbiome and facilitate 
selection and expansion of resistant bacteria [22]. Concurrent with increased understanding of 
the role of the commensal bacteria in preventing colonization and infection with CDI and VRE, 
as well as other MDROs, has prompted a look at use of microbiota-based approaches to 
prevent colonization and infection due to these organisms. Recent work has demonstrated 
commensal bacteria provide not only colonization resistance, but also are involved in immune 
processes that stimulate the development of antimicrobial factors [23]. Antimicrobials, by killing 
the commensal bacteria, decrease the diversity of the intestinal microbiota, enabling pathogens 
such as VRE and C. difficile, among others, to colonize and proliferate [24]. A normal intestinal 
microbiota, therefore, is necessary for colonization resistance. FMT has been demonstrated 
effective against recurrent CDI [25,26] and to restore diversity in the gut microbiota in 
successfully treated patients [27,28].         
  
Based on the positive experience with the use of FMT for recurrent CDI, FMT is now being 
considered for the treatment of many other conditions, and it has been suggested that it may be 
effective in clearing VRE and other MDROs by restoring colonization resistance [22,23].  Case 
reports have described the use of FMT for MDRO decolonization [29,30]. Jang et al. [29] 





















of CDI with FMT. However, VRE was cultured from the stool throughout the 3-month follow-up.  
Crum-Cianflone et al. [30] reported one case where FMT successfully cured relapsing CDI and 
several MDROs including VRE. Stripling, et al. reported that FMT cleared VRE and CDI in a 
woman with orthotopic cardiac and single cadaveric kidney transplants complicated by multiple 
episodes of VRE infection and CDI post-transplant. Between the time of organ transplants and 
FMT, the patient was hospitalized 18 times. The patient had no further CDI or VRE infections at 
1-year after FMT [31].  Singh et al. reported on eradication of extended spectrum beta-
lactamase (ESBL) producing Escherichia coli (E. coli) in a man with a renal allo-transplant with 
end-stage renal disease consequent to recurrent episodes of pyelonephritis post-transplant [32]. 
Following removal of the transplanted kidney, he remained colonized. Following FMT, the ESBL 
cleared at 12-weeks follow-up and he was then placed on the waiting list for renal 
transplantation.  
 
In this case series, RBX2660, a microbiota-based drug undergoing Phase 2 study for recurrent 
CDI, was associated with clearance of VRE in a high percentage of patients who were colonized 
at time of drug delivery (72.7%, 8/11). For two of the patients who failed to clear VRE, the 
treatment also failed to prevent recurrence of CDI. The recurrence of CDI in those patients may 
indicate that the gastrointestinal microbiota was not effectively reestablished after treatment with 
RBX2660. The proportion of patients with VRE detected in stool after the last dose of RBX2660 
decreased over the course of 6-month follow-up. Of note, it is possible RBX2660 suppressed 
VRE below the threshold of the culture method used to detect VRE colonization, as 
demonstrated by the patient in whom VRE was detected again after exposure to multiple 
courses of antimicrobials. Repeat exposures to antimicrobials are associated with persistence of 
VRE detection in stool [16-18]. Although VRE may no longer be detected in the absence of 
additional antimicrobial exposures, Donskey et al. [16] found VRE can be detected again when 





















(67%) patients positive at first test who converted to negative after RBX2660 who received 
additional antimicrobials after receipt of RBX2660. This suggests that VRE was truly “cleared” 
from the colon of several patients. It should be noted, however, that in some cases the absence 
of recurrence could potentially be related to antimicrobials with a low propensity to promote VRE 
colonization (e.g., fidaxomicin, doxycycline). RBX2660 may represent a potentially promising 
microbiota-based treatment strategy in a population with a well-documented risk of VRE 




The findings in this analysis have a number of limitations. This was a small secondary analysis 
conducted in the context of a Phase 2 open-label assessment of RBX2660 for recurrent CDI, 
and there was no comparator arm. However, natural history observation estimates a median 
time to clearance of VRE carriage at 26 weeks,4 whereas the majority of evaluable patients 
appeared to clear in a shorter interval.  Patient compliance with stool submission post-RBX2660 
administration varied over the course of follow-up. The findings should be confirmed in a larger 
study with VRE decolonization as a primary outcome using a placebo arm for comparison.   
 
Conclusions 
This secondary analysis demonstrates the possibility of converting a high percentage of VRE 
positive patients to negative with RBX2660. Based on an analysis of post-RBX2660 
antimicrobial exposure, it appears that the VRE conversion results may be durable. Additional 
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Table 1. Baseline Characteristics 
Parameter  Stool tested for VRE 
n=30  
Always VRE (-)  
n=19  
At least 1 VRE (+)      
n=11  
Entire PUNCH CD 
cohort 
n = 34  
     
Mean age, range, y  66.7 (26.7-89.5)  61.7 (26.7-77.8)  75.5 (47.6-89.5)  66.8 (26.7 – 89.6) 
Female sex, (%) 20 (66.6)  13 (68.4)  7 (63.6)  23 (67.6) 
Caucasian, (%) 29 (96.6)  19 (100)  10 (90.9)  32 (94.2) 
Mean BMI, range k/m2  24.4 (15-37)  23.9 (15-31)  25.3 (19-37)  24.4 (15-37) 
History of cardiovascular disease, %  16 (53.3)  10 (52.6)  6 (54.5)  19 (55.9) 
History of gastrointestinal comorbidity, %  18 (60)  11 (57.9)  7 (63.6)  21 (61.8) 
 
 





















Table 2. VRE Culture Results for Patients with at Least 1 Positive Culture for VRE 
Patient 
Number  
VRE Test Status  Antimicrobials 
Post RBX2660 
CDI Status 
 Baseline 7 days 30 days 60 days 6 months VRE  
Cleared 




















+ - - - - Yes None 1 Success 
4 
 
NA + NA - - Yes None 2 Success 
5 
 
NA + - - NA Yes None 2 Success 
6* 
 






















VRE = vancomycin resistant Enterococcus; CDI=Clostridium difficile infection; NA=not available  
VRE status reflects status after the last dose of RBX2660.   
* Died 35 days after last dose of RBX2660 of causes unrelated to drug administration; follow-up data on VRE status was unavailable.
7 
 
NA + + + + No Vancomycin, 1 2 Failure 
8 
 
NA - + - NA Yes None 2 Success 
9 
 






+ + - - - Yes None 1 Success 
11 
 


























Figure 1. The percentage of patients testing VRE positive after the last dose of RBX2660 
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